Problematic clinical isolates of Pseudomonas aeruginosa from the university hospitals in Sofia, Bulgaria: Current status of antimicrobial resistance and prevailing resistance mechanisms

Journal of Medical Microbiology

Volumn 56, Issue 7, 2007, Pages 956-963

  Strateva, Tanya ^a   Ouzounova Raykova, Vessela ^a   Markova, Boyka ^b   Todorova, Albena ^c   Marteva Proevska, Yulia ^b   Mitov, Ivan ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^c University Hospital of Obstetrics and Gynecology 'Maichin Dom' Bulgaria   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZLOCILLIN; AZTREONAM; BETA LACTAMASE; CARBENICILLIN; CEFEPIME; CEFOPERAZONE; CEFPIROME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BULGARIA; HOSPITAL INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STATISTICAL ANALYSIS; STRUCTURAL GENE; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BULGARIA; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEQUENCE ANALYSIS, DNA;

EID: 34447263017     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.46986-0     Document Type: Article

References (38)

1. Aminoglycoside Resistance Study Groups (1994). Resistance to aminoglycosides in Pseudomonas. Trends Microbiol 2, 347-353.
2. Bachvarova, A., Velinov, T., Petrov, M., Kantardjiev, T., Levterova, V. & Ivanov, I. (2005). Widespread detection of VEB-1-type extended-spectrum β-lactamases among nosocomial Pseudomonas aeruginosa isolates in Bulgaria: a nationwide multicentre study. Clin Microbiol Infect 11 (Suppl. 2), 233.
3. Bahar, G., Mazzariol, A., Koncan, R., Mert, A., Fontana, R., Rossolini, G. M. & Cornaglia, G. (2004). Detection of VIM-5 metallo-β-lactamase in a Pseudomonas aeruginosa clinical isolate from Turkey. J Antimicrob Chemother 54, 282-283.
4. Bert, F., Branger, C. & Lambert-Zechovsky, N. (2002). Identification of PSE and OXA β-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism. J Antimicrob Chemother 50, 11-18.
5. Bert, F., Ould-Hocine, Z., Juvin, M., Dubois, V., Loncle-Provot, V., Lefranc, V., Quentin, C., Lambert, N. & Arlet, G. (2003). Evaluation of the Osiris expert system for identification of β-lactam phenotypes in isolates of Pseudomonas aeruginosa. J Clin Microbiol 41, 3712-3718.
6. Blanc, D. S., Petignat, C., Janin, B., Bille, J. & Francioli, P. (1998). Frequency and molecular diversity of Pseudomonas aeruginosa upon admission and during hospitalization: a prospective epidemiologic study. Clin Microbiol Infect 4, 242-247.
7. Bush, K., Jacoby, G. A. & Medeiros, A. A. (1995). A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39, 1211-1233.
8. Claeys, G., Verschraegen, G., de Baere, T. & Vaneechoutte, M. (2000). PER-1 β-lactamase-producing Pseudomonas aeruginosa in an intensive care unit. J Antimicrob Chemother 45, 924-925.
9. De Champs, C., Poirel, L., Bonnet, R., Sirot, D., Chanal, C., Sirot, J. & Nordmann, P. (2002). Prospective survey of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 46, 3031-3034.
10. Empel, J., Filczak, K., Mrowka, A., Hryniewicz, W. & Gniadkowski, M. (2005). The first incidence of PER-1 ESBL-producing Pseudomonas aeruginosa in Poland and identification of a novel OXA β-lactamase variant. Clin Microbiol Infect 11 (Suppl. 2), 235.
11. Girlich, D., Naas, T., Leelaporn, A., Poirel, L., Fennewald, M. & Nordmann, P. (2002). Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-spectrum β-lactamase in Pseudomonas aeruginosa in Thailand. Clin Infect Dis 34, 603-611.
12. Hooper, D. C. (2001). Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 7, 337-341.
13. Jarlier, V., Nicolas, M. H., Fournier, G. & Philippon, A. (1988). Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 10, 867-878.
14. Lee, K., Chong, Y., Shin, H. B., Kim, Y. A., Yong, D. & Yum, J. H. (2001). Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 7, 88-91.
15. Lee, S., Park, Y. J., Kim, M., Lee, H. K., Han, K., Kang, C. S. & Kang, M. W. (2005). Prevalence of Ambler class A and D β-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimicrob Chemother 56, 122-127.
16. Livermore, D. M. (1992). Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 36, 2046-2048.
17. Livermore, D. M. (2001). Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 47, 247-250.
18. Llanes, C., Hocquet, D., Vogne, C., Benali-Baitich, D., Neuwirth, C. & Plesiat, P. (2004). Clinical strains of Pseudomonas aeruginosa overproducing MexA-MexB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother 48, 1797-1802.
19. Luzzaro, F., Mantengoli, E., Perilli, M., Lombardi, G., Orlandi, V., Orsatti, A., Amicosante, G., Rossolini, G. M. & Toniolo, A. (2001). Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase. J Clin Microbiol 39, 1865-1870.
20. Mavroidi, A., Tsakris, A., Tzelepi, E., Pournaras, S., Loukova, V. & Tzouvelekis, L. S. (2000). Carbapenem-hydrolyzing VIM-2 metallo-β-lactamase in Pseudomonas aeruginosa from Greece. J Antimicrob Chemother 46, 1041-1042.
21. McGowan, J. E. (2006). Resistance in nonfermenting Gram-negative bacteria: multidrug resistance to the maximum. Am J Med 119, S29-S36.
22. Naas, T., Poirel, L., Karim, A. & Nordmann, P. (1999). Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum β-lactamase VEB-1 in Pseudomonas aeruginosa. FEMS Microbiol Lett 176, 411-419.
23. Naas, T., Benaoudia, F., Massuard, S. & Nordmann, P. (2000). Integron-located VEB-1 extended-spectrum β-lactamase gene in a Proteus mirabilis clinical isolate from Vietnam. J Antimicrob Chemother 46, 703-711.
24. NCCLS (2004). Performance Standards for Antimicrobial Susceptibility Testing, 14th informational supplement, M100-S14. Wayne, PA: National Committee for Clinical Laboratory Standards.
25. Nordmann, P. (2002). Old and novel mechanisms of resistance to β-lactams in P. aeruginosa. In 7th ECC Symposium Anything new for P. aeruginosa?, 4-7 May 2002, Paris.
26. Nordmann, P. & Poirel, L. (2002). Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 8, 321-331.
27. Petrov, M., Hadjieva, N., Kantardjiev, T., Velinov, T. & Bachvarova, A. (2005). Surveillance of antimicrobial resistance in Bulgaria - a synopsis from BulSTAR 2003. Euro Surveill 10, 79-82.
28. Poirel, L., Naas, T., Guibert, M., Chaibi, E. B., Labia, R. & Nordmann, P. (1999). Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum β-lactamase encoded by an Escherichia coli integron gene. Antimicrob Agents Chemother 43, 573-581.
29. Poirel, L., Rotimi, V., Mokaddas, E., Karim, A. & Nordmann, P. (2001). VEB-1-like extended-spectrum β-lactamases in Pseudomonas aeruginosa, Kuwait. Emerg Infect Dis 7, 468-470.
30. Poole, K. (2005). Aminoglycoside resistance in Pseudomonas aerginosa. Antimicrob Agents Chemother 49, 479-487.
31. Poole, K., Gotoh, N., Tsujimoto, H., Zhao, Q., Wada, A., Yamasaki, T., Neshat, S., Yamagishi, J., Li, X. Z. & Nishino, T. (1996). Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug resistant strains of Pseudomonas aeruginosa. Mol Microbiol 21, 713-724.
32. VIM-1 in a clinical strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 46, 4026-4028.
33. Sanders, C. C. & Sanders, W. E. (1992). β-Lactam resistance in Gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 15, 824-839.
34. Sanschagrin, F., Couture, F. & Levesque, R. C. (1995). Primary structure of OXA-3 and phylogeny of oxacillin-hydrolyzing class D β-lactamases. Antimicrob Agents Chemother 39, 887-893.
35. Tassios, P. T., Gennimata, V., Spaliara-Kalogeropoulou, L., Kairis, D., Koutsia, C., Vatopoulos, A. C. & Legakis, N. J. (1997). Multiresistant Pseudomonas aeruginosa serogroup O:11 outbreak in an intensive care unit. Clin Microbiol Infect 3, 621-628.
36. Tsakris, A., Pournaras, S., Woodford, N., Palepou, M. F., Babini, G. S., Douboyas, J. & Livermore, D. M. (2000). Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 38, 1290-1292.
37. Vahaboglu, H., Ozturk, R., Aygun, G., Coskunkan, F., Yaman, A., Kaygusuz, A., Leblebicioglu, H., Balik, I., Aydin, K. & Otkun, M. (1997). Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 41, 2265-2269.
38. Weldhagen, G. F., Poirel, L. & Nordmann, P. (2003). Ambler class A extended-spectrum β-lactamases in Pseudomonas aeruginosa: novel developments and clinical impacts. Antimicrob Agents Chemother 47, 2385-2392.